Baxter International Earnings Mixed (BAX)

Baxter International BAX reported second quarter earnings Thursday morning sending mixed signals to investors. EPS beat the analyst consensus by 2.65 percent, coming in at $1.16 with revenue missing by almost one percent at 3.67 billion.

Baxter made advances with its HyQvia, RIXUBIS, and rigosertib products during the quarter. The company noted, “BioScience sales rose six percent driven primarily by improved demand for the company's hemophilia therapies, including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] and FEIBA (an inhibitor therapy), as well as accelerated growth of select specialty plasma-based therapeutics and vaccines.”

Related: FDA Approves Baxter's RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia B

Looking forward to the third quarter, Baxter expects sales growth from continuing operations to be around six percent. Third quarter EPS is expected to land between $1.18 and $1.21.

Shares of Baxter International traded almost one percent to $73.70 a few minutes after the open.